Market Overview

UPDATE: Goldman Sachs Downgrades NuVasive as Industry Headwinds, Valuation Pose Downside Risk

Related NUVA
82 Biggest Movers From Yesterday
66 Stocks Moving In Wednesday's Mid-Day Session
New Research Coverage Highlights Facebook, Korn/Ferry International, NuVasive, Sonic ... (GuruFocus)

In a report published Monday, Goldman Sachs analyst David H. Roman downgraded the rating on NuVasive (NASDAQ: NUVA) from Neutral to Sell, and lowered the price target from $25.00 to $22.00.

In the report, Goldman Sachs noted, “We downgrade NuVasive shares (NUVA) to Sell from Neutral and lower our 12-month price target to $22 from $25, representing 16% downside potential vs. 4% average upside for the rest of our coverage. We see the stock's valuation and recent outperformance (+3,600bp vs. the Russell 2000 ytd) as unwarranted given industry headwinds and potential downside to outer year numbers, notwithstanding 2012 underperformance. While lumbar fusion insurer pushback seems to have eased in recent quarters, our conversations with industry participants point toward pressure in other spinal implant categories, such as cervical (represents 10%-12% of NuVasive's sales and is expected to account for around 25%-30% of 2013E revenue growth). The ongoing OIG investigation into NuVasive's CMS reimbursement filings is also a risk that is hard to quantify or assess outcomes. Finally, on a like-for-like accounting basis, NUVA shares trade at significant premium to orthopaedic/SMID-cap peers – 77X P/E for 2014E vs. peer group at a 16X mean.”

NuVasive closed on Friday at $24.32.

Latest Ratings for NUVA

Nov 2018UBSInitiates Coverage OnSell
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2018BMO CapitalMaintainsMarket PerformMarket Perform

View More Analyst Ratings for NUVA
View the Latest Analyst Ratings

Posted-In: David H. Roman Goldman SachsAnalyst Color Downgrades Analyst Ratings


Related Articles (NUVA)

View Comments and Join the Discussion!

Latest Ratings

MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Deutsche Bank Initiates Coverage on Benefitfocus on Positive Long-Term Outlook

UPDATE: Goldman Sachs Downgrades Globus Medical as Execution, Share Gains are Offset by Valuation